k141_1666626_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.2	317	313	343	6.71e-48	162
k141_1666626_2	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	31.5	308	313	325	1.40e-45	156
k141_1666626_2	SARG|gb|AAA26793|ARO:3003748|oleC	31.7	306	313	325	2.75e-45	155
k141_1666626_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.3	230	313	258	1.44e-27	107
k141_1666626_2	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	24.6	321	313	351	5.03e-25	102
k141_1666626_2	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.6	321	313	351	6.93e-25	101
k141_1666626_2	SARG|gb|AAK76137.1|ARO:3000024|patA	26.3	209	313	564	1.28e-14	73.2
k141_1160320_5	SARG|gi|1004359922|gb|AMP42228.1|	25.6	434	606	639	3.38e-27	115
k141_1160320_5	SARG|AAY62597	24.8	435	606	639	1.06e-26	114
k141_1160320_5	SARG|YP_594556	23.7	434	606	639	1.42e-26	113
k141_1160320_5	SARG|gi|254967129|gb|ACT97610.1|	24.8	435	606	639	1.89e-26	113
k141_1160320_5	SARG|AJ222769.gene.p01	24.8	435	606	639	1.89e-26	113
k141_1160320_5	SARG|gi|168258996|gb|ACA23181.1|	24.8	435	606	639	1.89e-26	113
k141_1160320_5	SARG|gi|1028100281|ref|WP_063856416.1|	24.8	435	606	639	1.89e-26	113
k141_1160320_5	SARG|ACA23195	24.8	435	606	639	1.89e-26	113
k141_1160320_5	SARG|CAD13485	24.8	435	606	639	1.89e-26	113
k141_1160320_5	SARG|gi|104303742|gb|ABF72138.1|	24.8	435	606	639	2.51e-26	112
k141_364140_3	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	33.8	222	399	1024	9.18e-28	114
k141_364140_3	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.8	222	399	1024	9.18e-28	114
k141_364140_3	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.8	222	399	1024	3.01e-27	113
k141_364140_3	SARG|gb|CAA53189|ARO:3000521|mupA	33.8	222	399	1024	3.01e-27	113
k141_583232_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.1	225	230	232	1.32e-61	191
k141_583232_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.1	229	230	233	3.54e-59	185
k141_583232_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	42.0	224	230	229	8.90e-59	184
k141_583232_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.5	226	230	228	4.91e-58	182
k141_583232_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.1	224	230	231	1.52e-57	181
k141_583232_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.9	231	230	231	4.32e-57	180
k141_583232_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.7	227	230	231	6.12e-57	179
k141_583232_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.7	227	230	231	8.66e-57	179
k141_583232_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	42.7	227	230	231	1.73e-56	178
k141_583232_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	43.3	231	230	235	1.95e-56	178
k141_583232_3	CARD|gb|ABD30512.1|ARO:3000839|arlS	29.5	288	492	451	6.29e-29	117
k141_583232_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.0	287	492	370	1.77e-19	89.0
k141_2684526_2	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	22.8	259	388	314	1.71e-12	66.6
k141_511201_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	49.2	128	158	231	7.25e-41	135
k141_511201_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.1	145	158	232	2.10e-40	134
k141_511201_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.4	145	158	232	5.94e-40	133
k141_511201_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	52.4	124	158	235	2.56e-39	132
k141_511201_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	47.3	131	158	233	6.86e-39	130
k141_511201_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.3	173	158	229	1.74e-38	129
k141_511201_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	47.4	137	158	232	1.89e-38	129
k141_511201_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.8	178	158	231	2.60e-38	129
k141_511201_1	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.8	178	158	231	3.67e-38	129
k141_511201_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.8	178	158	231	5.18e-38	128
k141_511201_2	SARG|gb|AAV85982.1|ARO:3000535|macB	30.1	418	418	644	1.24e-41	154
k141_511201_2	SARG|gi|426326769|emb|CCK10228.1|	30.6	422	418	648	2.35e-38	145
k141_511201_2	SARG|gi|1035670474|ref|WP_064517458.1|	29.4	422	418	648	8.13e-38	144
k141_511201_2	SARG|gi|1035717981|ref|WP_064557480.1|	29.4	422	418	648	8.13e-38	144
k141_511201_2	SARG|gi|896325272|ref|WP_049294291.1|	29.4	419	418	648	8.13e-38	144
k141_511201_2	SARG|gi|639216333|ref|WP_024554080.1|	29.4	419	418	648	8.13e-38	144
k141_511201_2	SARG|gi|1020141879|ref|WP_063264839.1|	30.8	422	418	647	1.10e-37	143
k141_511201_2	SARG|gi|655997348|ref|WP_029038923.1|	30.8	422	418	647	1.10e-37	143
k141_511201_2	SARG|YP_001438541	30.8	426	418	647	1.50e-37	143
k141_511201_2	SARG|gi|938460528|ref|WP_054624864.1|	30.8	426	418	647	1.50e-37	143
k141_511201_3	SARG|gi|1022688710|ref|WP_063443532.1|	48.4	221	237	648	7.44e-68	219
k141_511201_3	SARG|gi|695793471|ref|WP_032707680.1|	48.0	221	237	648	2.04e-67	218
k141_511201_3	SARG|gi|895981299|ref|WP_049056431.1|	48.0	221	237	648	2.04e-67	218
k141_511201_3	SARG|gi|823281237|ref|WP_047037467.1|	48.0	221	237	648	2.04e-67	218
k141_511201_3	SARG|gi|895967513|ref|WP_049046752.1|	48.0	221	237	648	2.04e-67	218
k141_511201_3	SARG|gi|779903733|ref|WP_045374054.1|	48.0	221	237	648	2.04e-67	218
k141_511201_3	SARG|gi|823326845|ref|WP_047080664.1|	48.0	221	237	648	2.85e-67	218
k141_511201_3	SARG|gi|823302270|ref|WP_047057473.1|	48.0	221	237	648	2.85e-67	218
k141_511201_3	SARG|gi|976146774|ref|WP_059305359.1|	48.0	221	237	648	2.85e-67	218
k141_511201_3	SARG|gi|1022664304|ref|WP_063420886.1|	48.0	221	237	648	2.85e-67	218
k141_511201_4	SARG|gi|487980711|ref|WP_002053440.1|	30.3	145	588	446	2.18e-06	49.3
k141_511201_4	SARG|gi|490848588|ref|WP_004710651.1|	30.3	145	588	446	2.18e-06	49.3
k141_511201_4	SARG|gi|518287882|ref|WP_019458090.1|	29.7	145	588	446	6.63e-06	47.8
k141_4926_2	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.3	453	531	654	4.02e-35	138
k141_4926_2	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.3	453	531	670	4.38e-35	138
k141_4926_2	SARG|AAB51122	26.3	453	531	670	4.38e-35	138
k141_4926_2	SARG|Q08425	26.3	453	531	641	6.81e-35	137
k141_4926_2	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.3	453	531	657	7.46e-35	137
k141_4926_2	SARG|Z21523.gene.p01	26.3	453	531	657	7.46e-35	137
k141_4926_2	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.3	453	531	641	2.49e-33	133
k141_4926_2	SARG|AAZ79478	26.3	453	531	657	2.70e-33	133
k141_4926_2	SARG|Q52360	26.3	457	531	641	3.36e-33	132
k141_4926_2	SARG|P70882	26.3	457	531	641	3.36e-33	132
k141_1382727_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.2	230	297	255	8.92e-41	141
k141_1382727_2	SARG|gi|763399392|ref|WP_044256358.1|	36.3	223	297	648	1.71e-39	145
k141_1382727_2	SARG|gi|835330218|ref|WP_047457825.1|	35.9	223	297	648	3.23e-39	144
k141_1382727_2	SARG|YP_001453760	35.9	223	297	648	3.23e-39	144
k141_1382727_2	SARG|gi|992390012|ref|WP_061077002.1|	36.3	223	297	648	6.09e-39	143
k141_1382727_2	SARG|gi|671541568|ref|WP_031525212.1|	36.2	224	297	648	8.36e-39	143
k141_1382727_2	SARG|gi|754927849|ref|WP_042284850.1|	35.9	223	297	648	8.36e-39	143
k141_1382727_2	SARG|gi|970558766|ref|WP_058820271.1|	36.7	237	297	648	1.15e-38	142
k141_1382727_2	SARG|gi|912614197|ref|WP_050196089.1|	36.8	223	297	648	1.15e-38	142
k141_1382727_2	SARG|gi|554685678|ref|WP_023185565.1|	36.8	239	297	648	1.15e-38	142
k141_2976851_4	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	42.9	1048	1052	1024	1.54e-310	887
k141_2976851_4	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	42.9	1048	1052	1024	1.54e-310	887
k141_2976851_4	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	42.9	1051	1052	1033	1.34e-308	882
k141_2976851_4	SARG|gb|AEY83581|ARO:3000510|mupB	42.9	1051	1052	1033	1.34e-308	882
k141_2976851_4	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.9	1013	1052	1024	2.81e-308	881
k141_2976851_4	SARG|gb|CAA53189|ARO:3000521|mupA	43.9	1013	1052	1024	2.81e-308	881
k141_2976851_4	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	36.4	1092	1052	1107	1.65e-214	643
k141_2976851_4	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	36.4	1092	1052	1107	1.65e-214	643
k141_2977987_2	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	38.8	134	169	164	2.33e-30	107
k141_2977987_2	SARG|gb|BAE15963.1|ARO:3002868|dfrG	40.6	138	169	165	3.38e-30	107
k141_2977987_2	NCBI|WP_290468344.1|1|1|dfrL|dfrL|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrL|AMR|diaminopyrimidine	46.3	136	169	176	9.04e-30	106
k141_2977987_2	CARD|gb|CAC8536249.1|ARO:3007456|dfrL	46.3	136	169	193	1.40e-29	106
k141_2977987_2	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	38.2	157	169	163	1.81e-29	105
k141_2977987_2	SARG|gb|CBL80435.1|ARO:3002869|dfrK	37.6	157	169	163	3.60e-29	104
k141_2977987_2	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	37.6	157	169	163	3.60e-29	104
k141_2977987_2	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	42.2	135	169	166	3.90e-29	104
k141_2977987_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.8	229	234	307	1.11e-27	106
k141_2977987_6	SARG|gi|542061059|gb|ERI11611.1|	29.1	230	234	316	1.34e-24	98.2
k141_2977987_6	SARG|gi|447195835|ref|WP_001273091.1|	30.3	231	234	306	1.16e-23	95.5
k141_2977987_6	SARG|gi|447195836|ref|WP_001273092.1|	30.3	231	234	306	2.23e-23	94.7
k141_2977987_6	SARG|ZP_04081918	30.3	231	234	306	4.30e-23	94.0
k141_2977987_6	SARG|ABB80128	28.7	230	234	306	5.89e-22	90.9
k141_2977987_6	SARG|P42332	28.3	230	234	306	2.17e-21	89.4
k141_2977987_6	SARG|AAD21213	28.3	230	234	306	3.01e-21	89.0
k141_2977987_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.8	230	234	306	5.76e-21	88.2
k141_2977987_6	SARG|gi|510143239|gb|AGN36970.1|	27.8	230	234	313	6.30e-21	88.2
k141_445155_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.6	556	586	575	1.56e-98	310
k141_445155_1	SARG|gb|AAK76137.1|ARO:3000024|patA	32.8	540	586	564	8.30e-85	274
k141_445155_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.9	512	586	574	5.55e-50	181
k141_445155_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	25.0	575	586	579	1.57e-49	179
k141_445155_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.3	582	586	579	4.08e-49	178
k141_445155_1	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.8	400	586	579	1.35e-47	174
k141_445155_1	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.8	402	586	579	3.49e-47	173
k141_445155_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.0	503	586	664	1.90e-46	172
k141_445155_1	SARG|gb|AAK76136.1|ARO:3000025|patB	25.0	537	586	588	1.93e-46	171
k141_445155_1	SARG|gi|928900436|ref|WP_053931243.1|	26.2	576	586	600	1.09e-45	169
k141_445155_2	SARG|gb|AAK76136.1|ARO:3000025|patB	30.6	592	578	588	3.16e-85	275
k141_445155_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.7	505	578	664	9.93e-84	273
k141_445155_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	41.2	337	578	362	1.82e-78	251
k141_445155_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.9	531	578	582	6.30e-75	248
k141_445155_2	SARG|gi|948137056|ref|WP_056795395.1|	31.4	586	578	602	2.09e-71	239
k141_445155_2	SARG|gi|944152509|ref|WP_055644808.1|	30.8	587	578	616	2.81e-71	239
k141_445155_2	SARG|gi|928900436|ref|WP_053931243.1|	31.1	588	578	600	2.86e-70	236
k141_445155_2	SARG|gi|664579989|ref|WP_031094015.1|	31.1	588	578	601	2.92e-70	236
k141_445155_2	SARG|gi|944009777|ref|WP_055601444.1|	30.4	588	578	628	1.37e-69	235
k141_445155_2	SARG|gi|947982677|ref|WP_056642336.1|	30.3	587	578	626	3.56e-69	234
k141_1604898_2	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	30.2	215	253	325	1.26e-28	109
k141_1604898_2	SARG|gb|AAA26793|ARO:3003748|oleC	30.5	213	253	325	2.44e-28	108
k141_1604898_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.8	214	253	307	1.85e-26	103
k141_1171468_3	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	38.8	637	582	703	8.56e-124	379
k141_1968362_4	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.2	285	486	356	3.82e-24	102
k141_1968362_4	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	257	486	356	2.38e-23	100
k141_1968362_4	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.9	284	486	355	4.32e-23	99.4
k141_1968362_4	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.9	284	486	355	4.32e-23	99.4
k141_1968362_4	SARG|ACM47285	29.9	284	486	363	4.78e-23	99.4
k141_1968362_4	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.3	256	486	356	9.04e-22	95.5
k141_1968362_4	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.0	257	486	346	2.67e-21	94.0
k141_1968362_4	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.7	285	486	355	7.35e-21	92.8
k141_1968362_4	SARG|BAE96115	27.7	285	486	355	7.35e-21	92.8
k141_1968362_4	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	27.9	197	486	209	2.92e-13	67.8
k141_3273059_1	SARG|YP_001779894	37.0	73	171	212	1.97e-09	53.5
k141_3273059_1	SARG|YP_002861121	26.9	130	171	212	1.97e-09	53.5
k141_3273059_1	SARG|YP_001389621	35.6	73	171	212	5.13e-09	52.4
k141_304358_2	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	29.2	212	286	246	3.47e-21	89.0
k141_304358_2	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	33.0	188	286	243	8.53e-20	85.1
k141_304358_2	SARG|L22689.1.gene1.p01	29.6	223	286	257	3.50e-17	78.2
k141_304358_2	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	32.4	182	286	301	7.44e-16	75.1
k141_304358_2	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	31.9	182	286	301	1.02e-15	74.7
k141_304358_2	megares|MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42_1	31.9	182	286	303	1.04e-15	74.7
k141_2839224_6	SARG|gi|851935911|ref|WP_048224705.1|	33.0	203	205	660	1.75e-29	113
k141_2839224_6	SARG|B7LM76	33.0	200	205	660	3.87e-28	109
k141_2839224_6	SARG|gi|851917461|ref|WP_048217311.1|	32.5	203	205	660	7.19e-28	108
k141_2839224_6	SARG|gi|1002399350|ref|WP_061382108.1|	32.0	203	205	660	7.19e-28	108
k141_2839224_6	SARG|gi|489117806|ref|WP_003027650.1|	32.5	203	205	660	7.19e-28	108
k141_2839224_6	SARG|gi|696375142|ref|WP_032949690.1|	32.5	203	205	660	7.19e-28	108
k141_2839224_6	SARG|gi|507079934|ref|WP_016150692.1|	32.5	203	205	660	9.80e-28	108
k141_2839224_6	SARG|gi|765458296|ref|WP_044714032.1|	32.5	203	205	660	9.80e-28	108
k141_2839224_6	SARG|gi|851912779|ref|WP_048215868.1|	32.5	203	205	660	9.80e-28	108
k141_2839224_6	SARG|gi|851981245|ref|WP_048240645.1|	32.5	203	205	660	9.80e-28	108
k141_2115180_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.0	177	170	232	5.07e-42	139
k141_2115180_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	177	170	232	5.07e-42	139
k141_2115180_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.1	176	170	231	3.53e-39	132
k141_2115180_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.1	176	170	231	3.53e-39	132
k141_2115180_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.9	167	170	219	7.24e-39	130
k141_2115180_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.9	167	170	220	7.44e-39	130
k141_2115180_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.9	167	170	220	7.44e-39	130
k141_2115180_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.9	167	170	220	7.44e-39	130
k141_2115180_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.4	176	170	230	1.93e-38	130
k141_2115180_1	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.9	176	170	231	1.98e-38	130
k141_2115180_2	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.4	313	492	447	9.44e-28	114
k141_2115180_2	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.3	314	492	447	2.66e-26	110
k141_2115180_2	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.3	314	492	447	2.66e-26	110
k141_2115180_2	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.3	314	492	447	2.66e-26	110
k141_2115180_2	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.7	314	492	454	1.05e-24	105
k141_2115180_2	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	24.3	272	492	392	3.43e-24	103
k141_2115180_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	23.3	382	492	451	1.32e-20	93.2
k141_2115180_2	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	25.7	237	492	384	1.50e-19	89.4
k141_2115180_2	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	25.7	237	492	384	1.50e-19	89.4
k141_2115180_2	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.3	237	492	386	1.20e-18	86.7
k141_161072_3	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	21.4	173	396	397	4.84e-09	56.6
k141_161072_4	SARG|DQ018711.1.gene4.p01	41.3	315	328	322	2.90e-81	248
k141_161072_4	SARG|gi|737310392|ref|WP_035293250.1|	41.3	315	328	323	1.20e-80	247
k141_161072_4	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	40.9	318	328	343	4.40e-80	246
k141_161072_4	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	41.2	306	328	323	6.78e-80	245
k141_161072_4	SARG|gi|738848198|ref|WP_036737307.1|	41.0	315	328	323	3.84e-79	243
k141_161072_4	SARG|KF478993.1.gene2.p01	40.8	309	328	350	4.33e-79	244
k141_161072_4	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	41.8	316	328	348	5.77e-79	243
k141_161072_4	SARG|gi|740152780|ref|WP_037997109.1|	40.6	315	328	322	7.44e-79	242
k141_161072_4	SARG|gi|746609237|ref|WP_039635344.1|	39.8	319	328	322	7.44e-79	242
k141_161072_4	SARG|AF155139.2.gene6.p01	40.0	315	328	322	1.68e-77	239
k141_161072_6	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	31.9	144	184	159	8.64e-15	67.4
k141_161072_6	SARG|gi|1028848471|ref|WP_064017434.1|	35.5	107	184	206	7.53e-14	65.9
k141_161072_6	SARG|gi|670466162|ref|WP_031414939.1|	35.5	107	184	206	5.39e-13	63.5
k141_161072_6	SARG|gi|515720450|ref|WP_017153050.1|	30.5	164	184	210	2.91e-12	61.6
k141_161072_6	SARG|AF155139.2.gene5.p01	35.4	113	184	206	7.04e-11	57.8
k141_2988033_3	SARG|NP_390536	24.0	154	389	400	1.08e-07	52.4
k141_2988033_3	SARG|YP_002633439	23.0	152	389	388	1.79e-06	48.5
k141_2698760_1	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	29.6	253	301	633	3.18e-20	89.7
k141_1612714_5	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.1	581	593	579	1.76e-96	305
k141_1612714_5	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.7	584	593	579	6.11e-93	296
k141_1612714_5	SARG|gb|AAK76136.1|ARO:3000025|patB	35.1	485	593	588	4.20e-92	294
k141_1612714_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.9	490	593	664	3.19e-88	286
k141_1612714_5	SARG|gi|1045390184|ref|WP_065479071.1|	32.8	576	593	605	1.64e-87	282
k141_1612714_5	SARG|gi|516574297|ref|WP_017949361.1|	32.9	566	593	620	6.47e-87	281
k141_1612714_5	SARG|gi|695865802|ref|WP_032778631.1|	32.0	581	593	605	9.36e-86	278
k141_1612714_5	SARG|gi|1033217078|gb|OAR27197.1|	31.9	574	593	601	1.67e-85	277
k141_1612714_5	SARG|gi|695842130|ref|WP_032755430.1|	33.1	580	593	603	1.75e-85	277
k141_1612714_5	SARG|gi|505420018|ref|WP_015607120.1|	33.1	580	593	603	1.75e-85	277
k141_1612714_6	SARG|gi|827013130|ref|WP_047175495.1|	30.7	551	582	603	1.50e-75	250
k141_1612714_6	SARG|gi|951183771|ref|WP_057661487.1|	30.3	551	582	603	2.09e-75	250
k141_1612714_6	SARG|gi|948040364|ref|WP_056699531.1|	30.7	551	582	603	2.92e-75	249
k141_1612714_6	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.4	563	582	582	3.56e-75	249
k141_1612714_6	SARG|gi|695891735|ref|WP_032792824.1|	30.5	551	582	603	4.08e-75	249
k141_1612714_6	SARG|gi|928900436|ref|WP_053931243.1|	30.4	565	582	600	5.33e-75	249
k141_1612714_6	SARG|gi|943909899|ref|WP_055545300.1|	31.2	535	582	601	5.45e-75	249
k141_1612714_6	SARG|gi|913055317|ref|WP_050357634.1|	30.5	551	582	603	5.69e-75	249
k141_1612714_6	SARG|gi|764446018|ref|WP_044369325.1|	31.0	535	582	605	1.16e-74	248
k141_1612714_6	SARG|gi|1033217078|gb|OAR27197.1|	30.5	551	582	601	1.48e-74	248
k141_2770893_2	SARG|gb|AAK76136.1|ARO:3000025|patB	37.8	579	624	588	8.69e-118	362
k141_2770893_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	50.9	346	624	362	2.27e-110	335
k141_2770893_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.0	519	624	664	1.94e-104	329
k141_2770893_2	SARG|gi|928900436|ref|WP_053931243.1|	31.3	581	624	600	6.01e-88	284
k141_2770893_2	SARG|gi|664579989|ref|WP_031094015.1|	31.3	581	624	601	6.16e-88	284
k141_2770893_2	SARG|AF170880.4.gene1.p01	31.0	584	624	615	6.20e-88	285
k141_2770893_2	SARG|gi|558888514|ref|WP_023543283.1|	31.0	584	624	615	6.20e-88	285
k141_2770893_2	SARG|gi|639148059|ref|WP_024490169.1|	30.8	595	624	602	1.73e-87	283
k141_2770893_2	SARG|gi|1033217078|gb|OAR27197.1|	30.3	584	624	601	4.90e-86	279
k141_2770893_2	SARG|gi|948137056|ref|WP_056795395.1|	30.9	585	624	602	5.02e-86	279
k141_2770893_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	56.8	192	203	575	1.38e-69	221
k141_2770893_3	SARG|gb|AAK76137.1|ARO:3000024|patA	47.3	186	203	564	5.68e-53	177
k141_2770893_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	40.0	190	203	582	2.85e-40	143
k141_2770893_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	39.6	187	203	664	5.12e-40	143
k141_2770893_3	SARG|gi|928900436|ref|WP_053931243.1|	41.3	179	203	600	4.39e-39	140
k141_2770893_3	SARG|gi|664579989|ref|WP_031094015.1|	41.3	179	203	601	4.43e-39	140
k141_2770893_3	SARG|gi|702897513|ref|WP_033300957.1|	41.3	179	203	601	1.16e-38	139
k141_2770893_3	SARG|gi|953808775|ref|WP_058042812.1|	39.7	184	203	608	1.22e-38	139
k141_2770893_3	SARG|gi|664170108|ref|WP_030704355.1|	41.6	173	203	603	2.24e-38	138
k141_2770893_3	SARG|gi|501350226|ref|WP_012381861.1|	41.6	173	203	603	2.24e-38	138
k141_1614286_8	SARG|gi|779866095|ref|WP_045354445.1|	40.1	222	229	646	1.23e-41	148
k141_1614286_8	SARG|gi|779956086|ref|WP_045403603.1|	40.1	222	229	646	1.23e-41	148
k141_1614286_8	SARG|gi|981224618|ref|WP_059445588.1|	40.1	222	229	646	1.23e-41	148
k141_1614286_8	SARG|gi|1016275448|gb|AMX06027.1|	40.1	222	229	646	1.23e-41	148
k141_1614286_8	SARG|gi|895872463|ref|WP_048979698.1|	40.1	222	229	646	1.23e-41	148
k141_1614286_8	SARG|gi|836585048|ref|WP_047742322.1|	40.1	222	229	646	1.23e-41	148
k141_1614286_8	SARG|gi|695731723|ref|WP_032658224.1|	40.1	222	229	646	1.69e-41	148
k141_1614286_8	SARG|gi|1016942913|ref|WP_063144441.1|	40.1	222	229	646	1.69e-41	148
k141_1614286_8	SARG|gi|835749851|ref|WP_047648187.1|	40.1	222	229	646	1.69e-41	148
k141_1614286_8	SARG|gi|697052471|ref|WP_033145077.1|	40.1	222	229	646	1.69e-41	148
k141_1540543_3	SARG|gb|APB03219.1|ARO:3003986|TaeA	48.2	657	634	648	1.12e-198	572
k141_1540543_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	549	634	655	6.68e-61	213
k141_1540543_3	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	549	634	655	6.68e-61	213
k141_1540543_3	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	4.63e-60	211
k141_1540543_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	8.82e-60	210
k141_1540543_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	8.82e-60	210
k141_1540543_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	8.82e-60	210
k141_1540543_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	8.82e-60	210
k141_1540543_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	1.22e-59	210
k141_1540543_3	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	549	634	655	1.68e-59	209
k141_2483365_5	SARG|gi|488156254|ref|WP_002227462.1|	25.8	403	452	459	8.59e-18	84.3
k141_2483365_5	SARG|gi|488158065|ref|WP_002229273.1|	25.6	402	452	459	1.53e-17	83.6
k141_2483365_5	NCBI|EFF39147.1|1|1|norM-NG|norM-NG|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_NorM|AMR|efflux	25.4	402	452	459	8.69e-17	81.3
k141_2483365_5	SARG|NC_011035.1.6448920.p01	25.4	402	452	459	8.69e-17	81.3
k141_2483365_5	SARG|gi|489863287|ref|WP_003766901.1|	24.9	402	452	459	1.55e-15	77.4
k141_2483365_5	SARG|gi|487511179|ref|WP_001706772.1|	20.4	411	452	457	8.59e-15	75.1
k141_2483365_5	SARG|gi|554682163|ref|WP_023182103.1|	20.4	411	452	457	1.52e-14	74.3
k141_2483365_5	SARG|Q8Z6N7	20.4	411	452	457	1.52e-14	74.3
k141_2483365_5	SARG|gi|447097828|ref|WP_001175084.1|	20.4	411	452	457	1.52e-14	74.3
k141_2483365_5	SARG|ZP_02685717	20.4	411	452	457	1.52e-14	74.3
k141_1470042_6	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.5	113	145	232	3.76e-11	57.8
k141_1470042_6	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.5	113	145	232	3.76e-11	57.8
k141_1470042_6	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.6	107	145	232	9.90e-11	56.6
k141_1470042_6	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.6	107	145	232	9.90e-11	56.6
k141_1832816_3	SARG|YP_002333394	33.1	251	331	323	7.40e-31	117
k141_1832816_3	SARG|gi|498515089|ref|WP_010815296.1|	32.9	249	331	323	1.43e-30	117
k141_1832816_3	SARG|gi|985522333|ref|WP_060811962.1|	32.9	249	331	323	1.43e-30	117
k141_1832816_3	SARG|AF310956.2.gene5.p01	32.7	251	331	323	2.76e-30	116
k141_1832816_3	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	32.7	251	331	323	2.76e-30	116
k141_1832816_3	SARG|gb|AAB05626.1|ARO:3002943|vanHB	33.3	249	331	323	3.83e-30	115
k141_1832816_3	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	27.4	296	331	314	4.50e-30	115
k141_1832816_3	SARG|Q47748	32.9	249	331	323	5.32e-30	115
k141_1832816_3	SARG|AAF72362	31.5	276	331	323	1.41e-28	111
k141_2340759_4	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	36.7	221	247	325	4.15e-36	129
k141_2340759_4	SARG|gb|AAA26793|ARO:3003748|oleC	36.5	219	247	325	1.14e-35	128
k141_2340759_4	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.9	221	247	343	2.28e-35	127
k141_2340759_4	SARG|gi|500194536|ref|WP_011867743.1|	32.0	219	247	306	8.15e-35	125
k141_2340759_4	SARG|gi|447195836|ref|WP_001273092.1|	32.4	219	247	306	1.14e-34	125
k141_2340759_4	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	36.5	200	247	293	2.38e-34	124
k141_2340759_4	SARG|gi|447195835|ref|WP_001273091.1|	32.0	219	247	306	3.14e-34	124
k141_2340759_4	SARG|ZP_04081918	32.9	222	247	306	6.17e-34	123
k141_2340759_4	SARG|gi|500448961|gb|EOP61695.1|	30.4	217	247	306	2.37e-33	121
k141_2340759_4	SARG|gi|500465078|gb|EOP76697.1|	30.4	217	247	306	2.37e-33	121
k141_3428939_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.3	206	252	255	2.12e-52	169
k141_3428939_1	SARG|gb|AAV85982.1|ARO:3000535|macB	44.3	212	252	644	1.22e-47	166
k141_3428939_1	SARG|gi|922960663|ref|WP_053388845.1|	42.2	204	252	648	3.37e-47	164
k141_3428939_1	SARG|gi|495067432|ref|WP_007792257.1|	42.7	206	252	647	8.84e-47	163
k141_3428939_1	SARG|gi|757799695|ref|WP_043016897.1|	41.7	204	252	648	1.24e-46	163
k141_3428939_1	SARG|gi|1045891604|ref|WP_065554100.1|	41.7	204	252	648	1.24e-46	163
k141_3428939_1	SARG|gi|507082903|ref|WP_016153652.1|	41.7	204	252	648	1.24e-46	163
k141_3428939_1	SARG|gi|696368937|ref|WP_032943949.1|	41.7	204	252	648	1.24e-46	163
k141_3428939_1	SARG|gi|851913025|ref|WP_048215946.1|	41.7	204	252	648	1.24e-46	163
k141_3428939_1	SARG|gi|740856590|ref|WP_038641842.1|	41.7	204	252	648	1.24e-46	163
k141_2776642_4	SARG|gi|446110336|ref|WP_000188191.1|	39.5	233	234	648	1.94e-49	170
k141_2776642_4	SARG|gb|AAV85982.1|ARO:3000535|macB	41.0	229	234	644	1.32e-48	167
k141_2776642_4	SARG|gi|746243059|ref|WP_039291473.1|	38.4	232	234	648	1.86e-47	164
k141_2776642_4	SARG|gi|495736522|ref|WP_008461101.1|	38.4	232	234	648	9.48e-47	162
k141_2776642_4	SARG|gi|746253210|ref|WP_039301529.1|	38.4	232	234	648	9.48e-47	162
k141_2776642_4	SARG|gi|1001720867|ref|WP_061274204.1|	38.4	232	234	648	9.48e-47	162
k141_2776642_4	SARG|gi|895865878|ref|WP_048974758.1|	38.5	218	234	646	1.73e-45	159
k141_2776642_4	SARG|gi|1046630742|ref|WP_065696754.1|	38.1	218	234	646	2.39e-45	159
k141_2776642_4	SARG|gi|694064328|ref|WP_032410816.1|	37.6	218	234	646	4.39e-44	155
k141_2776642_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.8	229	234	664	7.20e-19	84.0
k141_3139637_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.4	161	229	231	1.60e-18	80.1
k141_3139637_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.6	187	229	247	1.99e-16	74.7
k141_3139637_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	28.0	182	229	229	7.74e-16	72.8
k141_3139637_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	29.3	147	229	233	2.87e-14	68.6
k141_3139637_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	25.2	206	229	252	3.08e-12	63.2
k141_316133_2	SARG|gb|AAG05187.1|ARO:3005067|ParS	26.3	255	393	428	1.94e-21	94.4
k141_318112_3	SARG|gb|AQX82857.1|ARO:3004185|mecD	23.1	437	579	678	7.31e-11	63.9
k141_461949_1	SARG|gi|922960663|ref|WP_053388845.1|	52.7	205	211	648	5.63e-68	218
k141_461949_1	SARG|gi|757799695|ref|WP_043016897.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|1045891604|ref|WP_065554100.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|507082903|ref|WP_016153652.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|696368937|ref|WP_032943949.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|851913025|ref|WP_048215946.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|740856590|ref|WP_038641842.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|489930965|ref|WP_003834285.1|	52.7	205	211	648	7.88e-68	218
k141_461949_1	SARG|gi|491270241|ref|WP_005128370.1|	52.7	205	211	648	1.54e-67	217
k141_461949_1	SARG|YP_002850060	52.7	205	211	648	1.54e-67	217
k141_461949_2	SARG|gi|559226183|ref|WP_023581296.1|	29.1	182	497	369	1.26e-11	65.1
k141_461949_2	SARG|gi|739066754|ref|WP_036938162.1|	29.6	189	497	369	2.97e-11	63.9
k141_461949_2	SARG|gi|857587769|emb|CRL59467.1|	28.6	189	497	369	2.20e-10	61.2
k141_461949_2	SARG|gi|1036665709|ref|WP_064719478.1|	27.9	190	497	369	2.15e-09	58.2
k141_461949_2	SARG|gi|857776688|emb|CRL63266.1|	29.3	181	497	358	3.64e-09	57.4
k141_461949_2	SARG|gi|896239619|ref|WP_049236948.1|	28.6	185	497	369	3.80e-09	57.4
k141_461949_2	SARG|gi|810389049|ref|WP_046335163.1|	28.6	185	497	369	3.80e-09	57.4
k141_461949_2	SARG|gi|983379772|ref|WP_060557066.1|	28.6	185	497	369	3.80e-09	57.4
k141_461949_2	SARG|CP004022.1.gene757.p01	28.6	185	497	369	3.80e-09	57.4
k141_461949_2	SARG|gi|490367950|ref|WP_004247613.1|	28.6	185	497	369	3.80e-09	57.4
k141_461949_3	SARG|gb|AAV85982.1|ARO:3000535|macB	32.6	411	406	644	4.52e-38	144
k141_461949_3	SARG|gi|896325272|ref|WP_049294291.1|	30.5	410	406	648	2.28e-33	130
k141_461949_3	SARG|gi|639216333|ref|WP_024554080.1|	30.5	410	406	648	2.28e-33	130
k141_461949_3	SARG|gi|494938585|ref|WP_007664615.1|	30.5	410	406	647	5.67e-33	129
k141_461949_3	SARG|YP_001438541	30.7	410	406	647	1.04e-32	129
k141_461949_3	SARG|gi|938460528|ref|WP_054624864.1|	30.7	410	406	647	1.04e-32	129
k141_461949_3	SARG|gi|490522515|ref|WP_004387938.1|	30.7	410	406	647	1.04e-32	129
k141_461949_3	SARG|gi|696420214|ref|WP_032990021.1|	30.7	410	406	647	1.04e-32	129
k141_461949_3	SARG|gi|922019548|ref|WP_053299973.1|	31.0	410	406	648	1.05e-32	129
k141_461949_3	SARG|gi|555230692|ref|WP_023217979.1|	31.0	410	406	648	1.05e-32	129
k141_2129203_2	SARG|Q83LR7	38.3	222	251	648	3.45e-41	148
k141_2129203_2	SARG|gi|647325472|ref|WP_025760953.1|	38.3	222	251	648	3.45e-41	148
k141_2129203_2	SARG|gi|647323678|ref|WP_025760497.1|	38.3	222	251	648	3.45e-41	148
k141_2129203_2	SARG|gi|446110305|ref|WP_000188160.1|	38.3	222	251	648	1.24e-40	146
k141_2129203_2	SARG|gi|446110311|ref|WP_000188166.1|	37.4	222	251	648	4.44e-40	145
k141_2129203_2	SARG|gi|446110301|ref|WP_000188156.1|	37.8	222	251	648	4.44e-40	145
k141_2129203_2	SARG|YP_403947	37.4	222	251	650	4.50e-40	145
k141_2129203_2	SARG|gi|1035735809|ref|WP_064572349.1|	37.8	222	251	648	6.11e-40	144
k141_2129203_2	SARG|gi|486160789|ref|WP_001524406.1|	37.8	222	251	648	6.11e-40	144
k141_2129203_2	SARG|gi|746217802|ref|WP_039267829.1|	37.8	222	251	648	6.11e-40	144
k141_1842716_2	SARG|HE999704.1.gene3064.p01	27.9	197	453	241	5.60e-16	76.3
k141_1842716_2	SARG|gi|441475675|emb|CCQ25429.1|	36.0	114	453	211	5.00e-13	67.0
k141_1338178_5	CARD|gb|AAD51347.1|ARO:3003067|smeS	25.7	202	213	467	1.04e-17	79.7
k141_2281253_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.5	117	376	231	4.90e-13	67.0
k141_2281253_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.2	117	376	232	6.74e-13	66.6
k141_2281253_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.2	120	376	228	7.22e-12	63.5
k141_2281253_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.9	127	376	219	1.17e-11	62.8
k141_2281253_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	121	376	219	5.32e-11	60.8
k141_2281253_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	121	376	219	5.32e-11	60.8
k141_2281253_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	121	376	220	5.39e-11	60.8
k141_2281253_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	121	376	220	7.29e-11	60.5
k141_2281253_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	121	376	220	9.86e-11	60.1
k141_2281253_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.2	116	376	229	4.97e-10	58.2
k141_468989_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.2	117	542	204	3.58e-06	47.0
k141_3077735_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	34.1	217	246	307	1.30e-37	132
k141_3077872_1	SARG|CP001581.1.gene725.p01	52.0	173	195	477	1.47e-56	184
k141_3077872_4	CARD|gb|CAL34518.1|ARO:3000526|cmeR	41.5	65	217	210	3.79e-06	45.1
k141_3077872_6	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	47.4	411	464	412	8.96e-128	375
k141_3077872_6	SARG|gb|ACJ63262.1|ARO:3003107|mefB	26.4	394	464	409	3.35e-26	108
k141_3077872_6	SARG|gb|QQM99829.1|ARO:3007047|mefH	41.7	103	464	109	9.09e-21	86.3
k141_3077872_6	SARG|ABI18324	27.2	378	464	405	2.98e-17	82.4
k141_3077872_6	SARG|gi|912934566|ref|WP_050313579.1|	27.5	378	464	405	3.99e-17	82.0
k141_3077872_6	SARG|gi|896624353|ref|WP_049505786.1|	27.5	378	464	405	3.99e-17	82.0
k141_3077872_6	SARG|gi|912699953|ref|WP_050238583.1|	26.8	380	464	405	5.35e-17	81.6
k141_3077872_6	SARG|gi|881045598|ref|WP_048764447.1|	27.5	378	464	405	5.35e-17	81.6
k141_3077872_6	SARG|gi|694120321|ref|WP_032461793.1|	27.5	378	464	405	5.35e-17	81.6
k141_3077872_6	SARG|AAK69027	27.5	378	464	405	5.35e-17	81.6
k141_1773271_2	SARG|CAP74085	39.1	64	198	210	1.23e-09	54.7
k141_1773271_2	SARG|AF015628.1.gene2.p01	41.8	67	198	212	3.25e-09	53.5
k141_1773271_2	SARG|ACA48664	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	SARG|ACD03314	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	SARG|AF445082.1.gene5.p01	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	SARG|AY259086.1.gene4.p01	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	NCBI|WP_071846350.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	NCBI|WP_071846363.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	37.5	64	198	210	1.54e-08	51.6
k141_1773271_2	SARG|AJ223604.1.gene5.p01	26.2	107	198	210	1.54e-08	51.6
k141_1341654_2	SARG|gb|AVI44920.1|ARO:3004470|poxtA	35.2	71	75	542	1.04e-09	51.6
k141_1341654_2	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	35.2	71	75	544	1.04e-09	51.6
k141_1341654_2	ResF|poxtA-Ef_1_WP094899500.1_1	36.6	71	75	538	6.08e-08	46.6
k141_1341654_2	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	36.6	71	75	543	6.08e-08	46.6
k141_1341654_2	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	36.6	71	75	543	6.08e-08	46.6
k141_1341654_2	SARG|gi|1046366091|gb|OCK16447.1|	41.7	48	75	498	1.39e-06	42.7
k141_1341654_2	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	40.8	49	75	461	1.90e-06	42.4
k141_1341654_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	36.6	71	75	648	1.93e-06	42.4
k141_1341654_2	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	40.8	49	75	461	2.60e-06	42.0
k141_1341654_2	SARG|gi|488243106|ref|WP_002314314.1|	42.0	50	75	492	2.61e-06	42.0
k141_328343_5	CARD|gb|BAB41874.1|ARO:3000815|mgrA	28.3	138	148	147	8.42e-21	81.6
k141_836196_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.7	504	473	703	9.27e-115	352
k141_836196_6	SARG|gi|1022688710|ref|WP_063443532.1|	46.6	221	236	648	1.97e-67	218
k141_836196_6	SARG|gi|823326845|ref|WP_047080664.1|	46.2	221	236	648	3.85e-67	217
k141_836196_6	SARG|gi|695793471|ref|WP_032707680.1|	46.2	221	236	648	5.39e-67	217
k141_836196_6	SARG|gi|895981299|ref|WP_049056431.1|	46.2	221	236	648	5.39e-67	217
k141_836196_6	SARG|gi|823281237|ref|WP_047037467.1|	46.2	221	236	648	5.39e-67	217
k141_836196_6	SARG|gi|895967513|ref|WP_049046752.1|	46.2	221	236	648	5.39e-67	217
k141_836196_6	SARG|gi|779903733|ref|WP_045374054.1|	46.2	221	236	648	5.39e-67	217
k141_836196_6	SARG|gi|823302270|ref|WP_047057473.1|	46.2	221	236	648	7.55e-67	216
k141_836196_6	SARG|gi|976146774|ref|WP_059305359.1|	46.2	221	236	648	7.55e-67	216
k141_836196_6	SARG|gi|1022664304|ref|WP_063420886.1|	46.2	221	236	648	7.55e-67	216
k141_836196_7	SARG|gb|AAV85982.1|ARO:3000535|macB	29.3	416	427	644	1.08e-38	146
k141_836196_7	SARG|gi|506220920|ref|WP_015740695.1|	28.4	415	427	647	2.59e-30	122
k141_836196_7	SARG|gi|1020141879|ref|WP_063264839.1|	28.2	415	427	647	2.59e-30	122
k141_836196_7	SARG|gi|655997348|ref|WP_029038923.1|	28.2	415	427	647	2.59e-30	122
k141_836196_7	SARG|YP_001438541	28.2	415	427	647	6.37e-30	121
k141_836196_7	SARG|gi|938460528|ref|WP_054624864.1|	28.2	415	427	647	6.37e-30	121
k141_836196_7	SARG|gi|490522515|ref|WP_004387938.1|	28.2	415	427	647	6.37e-30	121
k141_836196_7	SARG|gi|696420214|ref|WP_032990021.1|	28.2	415	427	647	6.37e-30	121
k141_836196_7	SARG|gi|639209604|ref|WP_024547784.1|	27.0	426	427	648	6.39e-30	121
k141_836196_7	SARG|gi|671541568|ref|WP_031525212.1|	27.7	426	427	648	6.39e-30	121
k141_836196_8	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	30.0	200	688	722	4.45e-17	84.3
k141_836196_11	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.4	207	366	258	9.13e-24	97.8
k141_691515_3	CARD|gb|ABD30512.1|ARO:3000839|arlS	23.5	370	452	451	7.36e-21	93.6
k141_691515_3	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.2	223	452	885	9.40e-12	66.2
k141_40690_3	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	42.9	224	232	225	2.89e-67	206
k141_40690_3	CARD|gb|AAC73788.1|ARO:3003841|kdpE	42.9	224	232	225	2.89e-67	206
k141_40690_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.4	226	232	232	3.63e-48	157
k141_40690_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.4	226	232	232	3.63e-48	157
k141_40690_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.5	221	232	228	2.89e-43	144
k141_40690_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.2	222	232	229	1.18e-42	143
k141_40690_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.2	223	232	231	1.39e-41	140
k141_40690_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.3	221	232	219	1.41e-41	140
k141_40690_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.6	226	232	233	8.21e-41	138
k141_40690_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.5	231	232	235	2.43e-40	137
k141_40690_4	CARD|gb|CYF42523.1|ARO:3004047|kdpD	23.4	512	491	885	1.08e-33	134
k141_40690_4	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.4	230	491	370	3.98e-20	90.9
k141_40690_4	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.5	268	491	392	3.88e-19	88.2
k141_40690_4	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.5	229	491	365	5.48e-19	87.4
k141_40690_4	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.4	231	491	380	2.75e-18	85.5
k141_40690_4	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.4	231	491	380	2.75e-18	85.5
k141_40690_4	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.2	232	491	381	1.20e-17	83.6
k141_40690_4	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.2	232	491	381	1.20e-17	83.6
k141_40690_4	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	232	491	381	2.99e-16	79.3
k141_40690_4	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	232	491	381	2.99e-16	79.3
k141_694684_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.0	224	230	231	7.48e-66	202
k141_694684_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.9	227	230	232	5.30e-61	190
k141_694684_3	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.3	227	230	231	8.30e-60	187
k141_694684_3	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.8	228	230	231	9.46e-59	184
k141_694684_3	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.4	227	230	231	9.46e-59	184
k141_694684_3	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.8	228	230	231	9.46e-59	184
k141_694684_3	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.4	227	230	231	2.68e-58	183
k141_694684_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.1	225	230	233	5.71e-58	182
k141_694684_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.6	229	230	232	2.22e-57	181
k141_694684_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.6	229	230	232	2.22e-57	181
k141_694684_4	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.0	304	386	359	6.37e-27	108
k141_694684_4	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.6	351	386	370	1.02e-26	108
k141_694684_4	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.0	250	386	364	7.81e-25	103
k141_694684_4	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.0	250	386	364	7.81e-25	103
k141_694684_4	SARG|gb|AAG05187.1|ARO:3005067|ParS	24.2	277	386	428	1.58e-24	103
k141_694684_4	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.2	290	386	365	2.77e-24	101
k141_694684_4	CARD|gb|AEX49906.1|ARO:3003583|basS	24.6	236	386	477	1.18e-22	98.2
k141_1494089_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.7	232	238	228	6.73e-63	195
k141_1494089_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.8	237	238	229	2.15e-56	178
k141_1494089_3	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.4	236	238	231	2.28e-56	178
k141_1494089_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.8	233	238	231	3.22e-56	178
k141_1494089_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.9	234	238	233	9.70e-56	177
k141_1494089_3	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	236	238	231	2.59e-55	176
k141_1494089_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	39.5	233	238	235	2.91e-55	176
k141_1494089_3	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.6	236	238	231	3.66e-55	175
k141_1494089_3	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.1	235	238	232	1.51e-54	174
k141_1494089_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	38.7	238	238	231	2.93e-54	173
k141_1494089_4	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	33.5	248	405	381	5.22e-35	132
k141_1494089_4	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	33.5	248	405	381	5.22e-35	132
k141_1494089_4	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	33.1	248	405	381	5.07e-34	129
k141_1494089_4	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	33.1	248	405	381	5.07e-34	129
k141_1494089_4	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.8	235	405	367	2.00e-33	127
k141_1494089_4	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.8	235	405	368	2.04e-33	127
k141_1494089_4	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	33.3	246	405	380	2.51e-33	127
k141_1494089_4	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	33.3	246	405	380	2.51e-33	127
k141_1494089_4	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.3	246	405	381	3.53e-33	127
k141_1494089_4	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.3	248	405	381	3.53e-33	127
k141_1856070_1	CARD|gb|ABD30512.1|ARO:3000839|arlS	29.8	285	472	451	1.48e-40	150
k141_1856070_1	CARD|gb|AEX49906.1|ARO:3003583|basS	26.0	242	472	477	4.66e-24	103
k141_1856070_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	22.2	252	472	370	2.14e-22	97.4
k141_1856070_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.4	223	235	219	4.88e-49	159
k141_1856070_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	37.1	229	235	225	1.16e-42	143
k141_1856070_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.5	228	235	229	1.30e-42	143
k141_1856070_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	36.7	229	235	225	4.61e-42	141
k141_1856070_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	35.9	231	235	235	2.67e-40	137
k141_1856070_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.6	227	235	231	2.66e-39	134
k141_1856070_2	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	33.8	222	235	231	2.57e-32	116
k141_117132_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.4	218	230	219	1.49e-46	152
k141_117132_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	230	219	3.73e-41	139
k141_117132_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	230	219	5.27e-41	138
k141_117132_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	230	220	5.42e-41	138
k141_117132_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	230	220	1.52e-40	137
k141_117132_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.7	221	230	220	2.66e-38	131
k141_117132_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.5	226	230	231	8.01e-33	117
k141_117132_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.9	220	230	228	4.45e-31	113
k141_117132_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.2	222	230	223	7.79e-31	112
k141_117132_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.9	225	230	232	9.67e-31	112
k141_3451277_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	37.3	225	230	885	4.13e-35	130
k141_3451277_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.9	235	230	370	6.18e-23	94.4
k141_3451277_1	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.1	228	230	367	1.01e-20	88.2
k141_3451277_1	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.1	228	230	368	1.02e-20	88.2
k141_3451277_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.6	232	230	365	4.50e-19	83.6
k141_3451277_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	234	230	381	5.47e-17	77.8
k141_3451277_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.5	234	230	381	5.47e-17	77.8
k141_3451277_1	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	28.6	220	230	357	1.22e-16	76.6
k141_3451277_1	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	28.6	220	230	357	1.22e-16	76.6
k141_3451277_1	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.2	230	230	354	5.02e-15	72.0
k141_3451277_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	42.7	225	233	225	1.09e-59	186
k141_3451277_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	42.7	225	233	225	1.09e-59	186
k141_3451277_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.8	223	233	231	1.15e-43	145
k141_3451277_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	34.2	225	233	231	2.56e-42	142
k141_3451277_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.2	225	233	231	2.56e-42	142
k141_3451277_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.2	226	233	232	5.25e-42	141
k141_3451277_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.2	226	233	232	5.25e-42	141
k141_3451277_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.8	225	233	231	1.02e-41	140
k141_3451277_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	32.2	230	233	233	1.52e-41	140
k141_3451277_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.1	225	233	231	2.02e-41	140
k141_412524_1	SARG|gi|446110305|ref|WP_000188160.1|	43.9	123	130	648	3.44e-30	112
k141_412524_1	SARG|Q83LR7	43.1	123	130	648	1.20e-29	110
k141_412524_1	SARG|gi|647325472|ref|WP_025760953.1|	43.1	123	130	648	1.20e-29	110
k141_412524_1	SARG|gi|647323678|ref|WP_025760497.1|	43.1	123	130	648	1.20e-29	110
k141_412524_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.8	122	130	255	1.20e-28	103
k141_412524_1	SARG|AAA50325	45.5	44	130	569	1.75e-06	44.7
k141_3237889_1	SARG|gb|AAC75314.1|ARO:3003578|pmrF	31.3	96	115	322	8.05e-10	53.5
k141_50594_2	SARG|gb|ABA71733.1|ARO:3002972|vanTG	36.0	372	393	712	6.87e-63	213
k141_50594_2	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	35.5	372	393	712	3.41e-58	200
k141_50594_2	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	34.0	373	393	711	1.90e-51	182
k141_50594_6	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	3.11e-113	352
k141_50594_6	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	4.38e-113	352
k141_50594_6	SARG|gb|AKA86814|ARO:3003746|optrA	40.7	506	638	655	4.38e-113	352
k141_50594_6	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	506	638	655	8.66e-113	351
k141_50594_6	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	506	638	655	8.66e-113	351
k141_50594_6	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	1.22e-112	351
k141_50594_6	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	1.71e-112	350
k141_50594_6	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	1.71e-112	350
k141_50594_6	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	1.71e-112	350
k141_50594_6	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.7	506	638	655	1.71e-112	350
k141_2297604_4	SARG|ZP_04528247	66.5	275	278	279	2.65e-119	342
k141_2297604_4	SARG|YP_002937728	65.1	278	278	289	1.01e-116	335
k141_2297604_4	SARG|ZP_03958019	63.8	279	278	317	5.25e-116	335
k141_2297604_4	SARG|YP_002929946	67.2	274	278	282	2.14e-114	329
k141_2297604_4	SARG|ZP_03984017	58.2	268	278	288	1.29e-97	287
k141_2297604_4	SARG|ZP_04433866	57.8	268	278	288	2.59e-97	286
k141_2297604_4	SARG|ZP_03949893	57.8	268	278	288	2.59e-97	286
k141_2297604_4	SARG|ZP_03938934	51.5	274	278	288	2.76e-89	266
k141_2297604_4	SARG|ZP_03941859	51.1	274	278	288	7.87e-89	265
k141_2297604_4	SARG|ZP_03945515	53.3	274	278	291	3.24e-86	258
k141_342187_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	35.1	211	243	307	1.33e-29	111
k141_921298_3	SARG|GQ205627.2.gene3.p01	44.6	65	168	216	5.61e-11	57.8
k141_921298_3	SARG|AF015628.1.gene2.p01	41.8	67	168	212	1.02e-10	57.0
k141_921298_3	SARG|AF368302.1.gene3.p01	42.7	75	168	204	3.41e-10	55.5
k141_921298_3	SARG|P50870	42.7	75	168	209	3.60e-10	55.5
k141_921298_3	SARG|AF139725.gene.p01	46.9	64	168	214	7.22e-10	54.7
k141_921298_3	SARG|AAF24171	46.9	64	168	214	7.22e-10	54.7
k141_921298_3	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	46.9	64	168	214	7.22e-10	54.7
k141_921298_3	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	46.9	64	168	214	7.22e-10	54.7
k141_921298_3	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	46.9	64	168	214	7.22e-10	54.7
k141_921298_3	SARG|AAG21695	46.9	64	168	214	7.22e-10	54.7
k141_3240856_4	SARG|AUI09862.1	50.0	94	97	287	1.19e-29	105
k141_1358176_1	SARG|gi|542061059|gb|ERI11611.1|	35.1	248	263	316	3.23e-33	122
k141_1358176_1	SARG|gi|447195835|ref|WP_001273091.1|	35.8	204	263	306	2.06e-31	117
k141_1358176_1	SARG|gi|447195836|ref|WP_001273092.1|	35.3	204	263	306	5.62e-31	115
k141_1358176_1	SARG|ZP_04081918	34.8	204	263	306	1.53e-30	114
k141_1358176_1	SARG|gi|500194536|ref|WP_011867743.1|	35.4	212	263	306	5.82e-30	113
k141_1358176_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.3	195	263	307	1.22e-26	104
k141_1358176_1	SARG|gi|498517610|ref|WP_010817605.1|	22.9	218	263	498	4.11e-11	61.6
k141_1358176_1	SARG|gi|498424272|ref|WP_010730861.1|	22.5	218	263	498	7.43e-11	60.8
k141_1358176_1	SARG|gi|498519697|ref|WP_010819589.1|	22.5	218	263	498	7.43e-11	60.8
k141_1358176_1	SARG|gi|488297611|ref|WP_002368819.1|	22.9	218	263	498	9.98e-11	60.5
k141_1937225_1	SARG|gb|ADZ12699.1|ARO:3005091|RanA	34.9	169	173	258	1.08e-27	103
k141_1937225_1	SARG|gi|507050365|ref|WP_016121371.1|	31.1	164	173	309	3.14e-23	92.4
k141_1937225_1	SARG|gi|895865878|ref|WP_048974758.1|	32.6	175	173	646	1.14e-22	92.8
k141_1937225_1	SARG|gi|500448961|gb|EOP61695.1|	30.5	164	173	306	1.14e-21	88.2
k141_1937225_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.0	180	173	362	3.38e-18	79.3
k141_1937225_1	SARG|gb|AAK76136.1|ARO:3000025|patB	29.7	182	173	588	8.68e-17	75.9
k141_1937225_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.1	166	173	664	8.91e-17	75.9
k141_1937225_1	SARG|gb|MBW0764195.1|ARO:3007027|salC	25.7	179	173	541	4.55e-11	59.3
k141_1937225_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.2	168	173	579	1.57e-10	57.8
k141_1937225_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.2	168	173	579	3.92e-10	56.6
k141_345721_6	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	52.8	159	160	159	3.05e-53	165
k141_1362723_1	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	27.8	108	983	233	1.61e-07	52.4
k141_3173996_4	SARG|gb|AAK76136.1|ARO:3000025|patB	30.0	220	269	588	1.10e-18	84.3
k141_3173996_4	SARG|gi|930482089|ref|WP_054228897.1|	26.7	236	269	599	4.99e-18	82.4
k141_3173996_4	SARG|gi|985844137|ref|WP_060895163.1|	26.7	236	269	599	4.99e-18	82.4
k141_3173996_4	SARG|gi|664556405|ref|WP_031071225.1|	26.7	236	269	602	6.76e-18	82.0
k141_3173996_4	SARG|gi|1011969930|ref|WP_062776015.1|	25.0	236	269	601	1.23e-17	81.3
k141_3173996_4	SARG|gi|662754041|ref|WP_030125200.1|	26.7	236	269	601	2.25e-17	80.5
k141_3173996_4	SARG|gi|664100597|ref|WP_030638327.1|	26.7	236	269	601	4.09e-17	79.7
k141_3173996_4	SARG|gi|505389066|ref|WP_015576168.1|	26.7	236	269	601	4.09e-17	79.7
k141_3173996_4	SARG|gi|503923650|ref|WP_014157644.1|	26.7	236	269	601	4.09e-17	79.7
k141_3173996_4	SARG|gi|943896259|ref|WP_055534530.1|	24.6	236	269	601	7.46e-17	79.0
k141_3322649_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.1	102	109	232	1.08e-23	89.7
k141_3322649_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.1	102	109	232	1.08e-23	89.7
k141_3322649_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	43.6	94	109	235	8.83e-23	87.4
k141_3322649_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.5	92	109	231	6.79e-21	82.4
k141_3322649_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.2	95	109	233	7.03e-21	82.4
k141_3322649_1	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.2	104	109	231	9.53e-21	82.0
k141_3322649_1	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.2	104	109	231	9.53e-21	82.0
k141_3322649_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.1	104	109	231	2.63e-20	80.9
k141_3322649_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.1	104	109	231	2.63e-20	80.9
k141_3322649_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.5	92	109	231	3.69e-20	80.5
k141_3322649_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	35.1	222	535	381	5.83e-26	108
k141_3322649_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	35.1	222	535	381	5.83e-26	108
k141_3322649_2	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	34.2	222	535	381	1.45e-25	107
k141_3322649_2	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	34.2	222	535	381	1.45e-25	107
k141_3322649_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	35.0	214	535	381	3.59e-25	106
k141_3322649_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	35.0	214	535	381	3.59e-25	106
k141_3322649_2	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	34.7	222	535	381	4.86e-25	105
k141_3322649_2	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	34.7	222	535	381	4.86e-25	105
k141_3322649_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.9	349	535	361	3.55e-19	88.2
k141_3322649_2	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	42.2	64	535	233	3.49e-06	47.4
k141_3322649_4	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	38.2	228	287	343	9.39e-47	159
k141_3322649_4	SARG|ABB80128	39.4	251	287	306	1.49e-46	157
k141_3322649_4	SARG|P42332	39.0	251	287	306	5.82e-46	155
k141_3322649_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	38.6	251	287	306	1.62e-45	154
k141_3322649_4	SARG|gi|510143239|gb|AGN36970.1|	38.6	251	287	313	1.93e-45	154
k141_3322649_4	SARG|AAD21213	41.9	215	287	306	1.25e-44	152
k141_3322649_4	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	36.3	212	287	325	3.01e-43	149
k141_3322649_4	SARG|gb|AAA26793|ARO:3003748|oleC	36.7	210	287	325	5.93e-43	148
k141_3322649_4	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	38.1	202	287	293	5.22e-39	137
k141_3322649_4	SARG|gb|ADZ12699.1|ARO:3005091|RanA	37.9	198	287	258	9.31e-38	133
k141_931832_6	SARG|gb|AAK76137.1|ARO:3000024|patA	25.2	214	260	564	1.35e-14	72.0
k141_931832_6	SARG|gb|WP_104671188.1|ARO:3003948|efrA	23.9	218	260	575	4.50e-14	70.5
k141_570993_2	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	32.9	277	319	337	1.42e-31	119
k141_570993_2	SARG|AAR37059	32.6	276	319	323	7.93e-31	117
k141_570993_2	SARG|AAD51059	32.4	272	319	323	2.13e-30	116
k141_570993_2	SARG|AAD41881	32.4	272	319	323	2.13e-30	116
k141_570993_2	SARG|gi|552942232|ref|WP_023043160.1|	31.9	276	319	323	2.96e-29	113
k141_570993_2	SARG|KF478993.1.gene2.p01	31.6	282	319	350	6.49e-29	112
k141_570993_2	SARG|AAD42183	32.4	272	319	322	1.08e-28	111
k141_570993_2	SARG|YP_002333394	31.8	286	319	323	2.12e-28	110
k141_570993_2	SARG|AY082011.1.gene6.p01	31.5	276	319	323	2.12e-28	110
k141_570993_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	31.7	287	319	323	2.12e-28	110
k141_2019140_4	SARG|gi|446048013|ref|WP_000125868.1|	30.1	156	154	648	5.25e-13	64.3
k141_2889528_4	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.1	220	682	361	2.02e-13	71.2
k141_2889528_4	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	22.0	246	682	359	1.10e-10	62.8
k141_2889528_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.3	119	682	228	4.65e-10	59.3
k141_2889528_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.3	161	682	219	4.49e-09	56.2
k141_2889528_4	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	23.6	212	682	341	1.69e-08	55.8
k141_2889528_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.1	121	682	231	4.18e-08	53.5
k141_2889528_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.5	120	682	220	4.94e-08	53.1
k141_2889528_4	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.3	108	682	223	5.13e-08	53.1
k141_2889528_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.4	130	682	220	8.96e-08	52.4
k141_2889528_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.7	120	682	219	2.90e-07	50.8
k141_2315235_6	SARG|KF478993.1.gene2.p01	39.2	288	346	350	5.15e-64	206
k141_2315235_6	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	39.1	289	346	348	1.51e-62	202
k141_2315235_6	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	38.9	288	346	343	1.85e-62	201
k141_2315235_6	SARG|gi|746609237|ref|WP_039635344.1|	38.1	278	346	322	4.07e-62	200
k141_2315235_6	SARG|DQ018711.1.gene4.p01	37.1	286	346	322	1.14e-61	199
k141_2315235_6	SARG|gi|737310392|ref|WP_035293250.1|	36.7	286	346	323	3.29e-61	197
k141_2315235_6	SARG|AF155139.2.gene6.p01	37.1	286	346	322	6.36e-61	197
k141_2315235_6	SARG|AAD41881	35.2	315	346	323	1.83e-60	196
k141_2315235_6	SARG|AAD51059	35.6	315	346	323	3.63e-60	195
k141_2315235_6	SARG|gi|740152780|ref|WP_037997109.1|	36.0	286	346	322	1.39e-59	193
k141_2389122_2	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	47.7	222	225	223	7.43e-73	219
k141_2389122_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.0	222	225	229	1.42e-31	114
k141_2389122_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.9	226	225	247	1.67e-30	112
k141_2389122_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.1	222	225	228	1.63e-29	108
k141_2389122_2	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	28.2	202	225	225	8.11e-24	94.0
k141_2389122_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	29.2	233	225	252	1.94e-23	93.6
k141_2389122_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	25.7	222	225	233	4.03e-17	76.3
k141_3185343_3	SARG|gi|493734654|ref|WP_006683876.1|	38.9	252	252	648	1.59e-44	157
k141_3185343_3	SARG|gi|936194420|ref|WP_054528571.1|	39.4	236	252	648	5.77e-44	155
k141_3185343_3	SARG|gi|740856590|ref|WP_038641842.1|	39.6	235	252	648	7.97e-44	155
k141_3185343_3	SARG|gi|754951242|ref|WP_042307417.1|	39.6	235	252	648	1.10e-43	155
k141_3185343_3	SARG|gi|829942568|ref|WP_047368199.1|	41.3	235	252	646	1.49e-43	154
k141_3185343_3	SARG|gi|757799695|ref|WP_043016897.1|	40.5	227	252	648	2.09e-43	154
k141_3185343_3	SARG|gi|491270241|ref|WP_005128370.1|	39.1	235	252	648	2.09e-43	154
k141_3185343_3	SARG|gi|1045891604|ref|WP_065554100.1|	40.5	227	252	648	2.09e-43	154
k141_3185343_3	SARG|gi|507082903|ref|WP_016153652.1|	40.5	227	252	648	2.09e-43	154
k141_3185343_3	SARG|gi|851913025|ref|WP_048215946.1|	39.1	235	252	648	2.09e-43	154
k141_288819_4	CARD|gb|BAA15221.2|ARO:3000263|marA	29.0	93	260	127	2.22e-07	47.8
